505 related articles for article (PubMed ID: 24780456)
21. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
22. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
23. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
24. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.
Banerjee D; Winocour P; Chowdhury TA; De P; Wahba M; Montero R; Fogarty D; Frankel AH; Karalliedde J; Mark PB; Patel DC; Pokrajac A; Sharif A; Zac-Varghese S; Bain S; Dasgupta I;
BMC Nephrol; 2022 Jan; 23(1):9. PubMed ID: 34979961
[TBL] [Abstract][Full Text] [Related]
25. Treating hypertension in the patient with overt diabetic nephropathy.
Lewis EJ
Semin Nephrol; 2007 Mar; 27(2):182-94. PubMed ID: 17418687
[TBL] [Abstract][Full Text] [Related]
26. Hypertensive nephropathy: prevention and treatment recommendations.
Hart PD; Bakris GL
Expert Opin Pharmacother; 2010 Nov; 11(16):2675-86. PubMed ID: 20718588
[TBL] [Abstract][Full Text] [Related]
27. Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
Rossing P; Parving HH; de Zeeuw D
Nephrol Dial Transplant; 2006 Sep; 21(9):2354-7; discussion 2357-8. PubMed ID: 16928724
[No Abstract] [Full Text] [Related]
28. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
Slagman MC; Navis G; Laverman GD
Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
[TBL] [Abstract][Full Text] [Related]
29. Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population.
Afghahi H; Miftaraj M; Svensson AM; Hadimeri H; Gudbjörnsdottir S; Eliasson B; Svensson MK;
J Diabetes Complications; 2013; 27(3):229-34. PubMed ID: 23246248
[TBL] [Abstract][Full Text] [Related]
30. The current state of RAAS blockade in the treatment of hypertension and proteinuria.
Kalaitzidis RG; Bakris GL
Curr Cardiol Rep; 2009 Nov; 11(6):436-42. PubMed ID: 19863868
[TBL] [Abstract][Full Text] [Related]
31. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
32. Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?
Majewski C; Bakris GL
Curr Diab Rep; 2016 Apr; 16(4):24. PubMed ID: 26879307
[TBL] [Abstract][Full Text] [Related]
33. Microalbuminuria as a target to improve cardiovascular and renal outcomes.
Basi S; Lewis JB
Am J Kidney Dis; 2006 Jun; 47(6):927-46. PubMed ID: 16731288
[TBL] [Abstract][Full Text] [Related]
34. Novel effective drugs for diabetic kidney disease? or not?
Gentile G; Mastroluca D; Ruggenenti P; Remuzzi G
Expert Opin Emerg Drugs; 2014 Dec; 19(4):571-601. PubMed ID: 25376947
[TBL] [Abstract][Full Text] [Related]
35. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Burnier M; Zanchi A
J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
[TBL] [Abstract][Full Text] [Related]
36. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
[TBL] [Abstract][Full Text] [Related]
37. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
St Peter WL; Odum LE; Whaley-Connell AT
Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
[TBL] [Abstract][Full Text] [Related]
38. Should albuminuria be a therapeutic target in patients with hypertension and diabetes?
de Zeeuw D
Am J Hypertens; 2004 Nov; 17(11 Pt 2):11S-15S; quiz A2-4. PubMed ID: 15539105
[TBL] [Abstract][Full Text] [Related]
39. Optimizing antihypertensive therapy in patients with diabetic nephropathy.
Ritz E; Rychlík I; Miltenberger-Miltenyi G
J Hypertens Suppl; 1998 Sep; 16(7):S17-22. PubMed ID: 9855027
[TBL] [Abstract][Full Text] [Related]
40. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
